At AACR, Experts Discuss Benefits and Challenges of Incorporating NGS in Clinical Trials | GenomeWeb

SAN DIEGO — Incorporating next-generation sequencing in the context of oncology clinical trials has many potential benefits as well as hurdles, according to a number of researchers that presented this week at the American Association for Cancer Research meeting in San Diego.

Researchers are starting to use sequencing both retrospectively to analyze exceptional responders to drugs — a strategy that can be employed to rescue failed trials — and also prospectively to match patients to a specific arm of a trial based on their mutational profile.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.